Stockwinners Market Radar for September 10, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:19 EDT DocuSign COO sells 5.8K shares of common stock - In a regulatory filing, DocuSign disclosed that its COO Scott Olrich sold 5.8K shares of common stock on September 9th in a total transaction size of $1.22M.

19:46 EDT Rio Tinto CEO J-S Jacques to step down - The company states: "Following the publication on 24 August 2020 of the Board Review of Cultural Heritage Management, undertaken in response to the destruction of the Juukan rockshelters in May 2020, the Board of Rio Tinto has engaged extensively with shareholders, Traditional Owners, Indigenous leaders and other stakeholders. While there is general recognition of the transparency of the Board Review and support for the changes recommended, significant stakeholders have expressed concerns about executive accountability for the failings identified.By mutual agreement, J-S Jacques will step down from his role as an executive director and Chief Executive of the Group. A process to identify his successor is underway. J-S will remain in his role until the appointment of his successor or 31 March 2021, whichever is earlier. This will ensure business continuity to maintain the strong performance of the Group's global operations during COVID-19."

18:25 EDT Epic says Apple provides extension on supporting 'Sign In with Apple' - Epic's Twitter account for "Fortnite" said that while Apple (AAPL) stated they would terminate "Sign In with Apple" support for Epic Games accounts after Sept 11, 2020, today the tech giant provided an indefinite extension. "We still recommend you prepare your accounts now for "Sign In with Apple" removal," Epic said. Investors in Epic include Tencent (TCEHY), KKR (KKR), Disney (DIS), and Sony (SNE). Reference Link

18:05 EDT Lyra Therapeutics presents clinical data of LYR-210 in chronic rhinosinusitis - Lyra Therapeutics presented data showing that LYR-210 demonstrated a "significant reduction" of sinonasal Type 2 inflammation in surgically naive patients with chronic rhinosinusitis. The reduction of Type 2 inflammation suggests a correlation with rhinologic symptom improvement in CRS and could be a potential measure of LYR-210's local anti-inflammatory effects at the site of inflammation in the sinonasal passages. The results showing LYR-210's influence on local Type 2 inflammatory response in CRS patients are secondary findings from the company's Phase 1 clinical study of LYR-210. The clinical finding of LYR-210's effect on Type 2 inflammation is presented as one of three poster presentations made by Lyra and its research collaborators at the 66th Annual Meeting of the American Rhinologic Society. LYR-210 significantly reduced sinonasal T2 inflammation markers IL-13, CCL26 and periostin in surgically naive CRS patients with and without polyps. Other T2 markers, IL-5 and CCL18, showed a trend toward reduction with LYR-210. Patients treated with a single administration of LYR-210 reported rapid, durable and clinically relevant improvement in CRS symptoms over the 24-week study.

17:36 EDT Inphi CFO sells 11K shares of common stock - In a regulatory filing, Inphi disclosed that its CFO John Edmunds sold 11.0K shares of common stock on September 9th in a total transaction size of $1.14M.

17:31 EDT Goosehead Insurance CEO sells 20.7K shares of common stock - In a regulatory filing, Goosehead Insurance disclosed that its CEO Mark Evan Jones sold 20.7K shares of common stock on September 9th in a total transaction size of $2.07M.

17:23 EDT Peloton to invest in new products, scaling production - Says will invest in new products and scaling production. Says resuming treadmill and bike shipments in nearly all regions. Says Tread+ had minimal revenue impact on the quarter. Says guidance reflects "substantial refunds" which had an impact on revenue in the period. Says price reductions and refunds will affect Q1 revenue. Says introduction of new treadmill will have minimal impact on revenue in FY21, but will have greater impact in FY22.

17:21 EDT A-Mark Precious Metals to pay $1.50 per share special dividend - A-Mark's Board of Directors approved a special dividend of $1.50 per common share. The special dividend will be paid on or about September 25, 2020 to stockholders of record as of September 21, 2020.

17:14 EDT Peloton sees treadmill as bigger opportunity than bikes - Sees treadmill as bigger opportunity than bikes. Says remains "very excited" about Peloton Digital. Sees digital subscriptions growth tapering.

17:04 EDT Oracle CEO says SaaS momentum very strong, will continue to get even better - Says will not make any comments on TikTok speculation. Comments taken from Q1 earnings conference call.

17:00 EDT Northern Oil and Gas provides operations update - The company said, "Northern has seen steady and marked improvement in operations throughout the third quarter of 2020. Realized oil pricing differentials have narrowed from wide levels experienced in the second quarter. Northern also expects a significant reduction in per unit lease operating expenses in the third quarter compared to the second quarter. Operators have continued to return shut-in and curtailed production to sales at a steady rate, at or above Northern's internal forecasts. Northern is adjusting its third quarter of 2020 production guidance upward from 22,500 - 30,000 Boe per day to 25,000 - 30,000 Boe per day, an increase of 1,250 Boe per day at the midpoint. Inclusive of today's announced acquisition, Northern continues to be well within its stated capital budget of $175 - 200 million for 2020 and does not currently anticipate accessing its $50 million reserve budget for accelerated completions."

16:45 EDT CNA names Santosh Bardwaj chief data & analytics officer - CNA announced the appointment of Santosh Bardwaj as Senior Vice President, Chief Data & Analytics Officer, effective September 14, 2020. In this role, Bardwaj will have oversight and leadership for CNA's enterprise data and analytics function, and will report to Michael Costonis, Executive Vice President & Chief Operations Officer. "Santosh's proven track record and strong leadership acumen, coupled with the depth of experience driving advanced analytics transformation, makes him the ideal candidate for Chief Data & Analytics Officer," Costonis said. "Under Santosh's leadership, CNA will extend and accelerate our advanced analytics and data science capabilities across the insurance value chain, leveraging cutting-edge, cloud-based technologies and partnerships."

16:45 EDT Athenex CEO Lau buys over $112K in shares - Athenex CEO Yiu-Nam Lau purchased 10,000 shares of company stock for $11.22 per share on September 10 for a total transaction of $112,200.

16:40 EDT Zumiez up 9.5% at $27.59 per share after Q2 results, Q3 sales update

16:38 EDT Zumiez sees Q3 QTD sales down 14% - Zumiez states: "The Company is providing quarter-to-date sales through Labor Day, Monday September 7th, as this time period is more comparable to the prior year given the shift in the Labor Day holiday. Total third quarter-to-date sales for the 37 days ending September 7, 2020 were down approximately 14%, compared with the same 37 day time period in the prior year ended September 9, 2019. Total comparable sales for the 37 day period ending September 7, 2020 were down 5.1%. By channel, open store comparable sales decreased 10.7% and e-commerce sales increased 27.4%."

16:33 EDT IBM, ESPN announce Trade Assistance with IBM Watson - IBM (IBM) and Disney's (DIS) ESPN announced Trade Assistant with IBM Watson, a new feature to the ESPN Fantasy Football app designed to help fantasy football players make more informed, fair trades throughout the 2020 season. The feature builds on ESPN and IBM's efforts to make playing Fantasy Football more engaging by utilizing artificial intelligence. Trade Assistant with IBM Watson is designed to reduce the complexities of fantasy football trades by suggesting trades that assess the fairness and value of a proposed trade - helping fantasy football players make smarter, more informed decisions. Trade Assistant with IBM Watson will assess the value of a player on a roster, the cost of losing a player and the equity involved in a trade. The new IBM feature is integrated only into ESPN Fantasy Football apps.

16:30 EDT Graham Holdings to repurchase up to 500,000 class B shares - Graham Holdings Company announced that its board of directors has authorized the company to acquire up to 500,000 shares of its Class B common stock. The company did not announce a ceiling price or time limit for the purchases.

16:25 EDT Invesco reports August AUM up 4.2% sequentially to $1.25B - Invesco reported preliminary month-end assets under management of $1.25B, an increase of 4.2% versus previous month-end. The firm achieved total net inflows of $6.9B this month. Overall net long-term inflows were $2.4B. Non-management fee earning net inflows were $3.8B and money market net inflows were $0.7B. AUM was positively impacted by favorable market returns, which increased AUM by $40B. FX increased AUM by $3.5B. Preliminary average total AUM for the quarter through August 31 were $1.2B, and preliminary average active AUM for the quarter through August 31 were $895.2B.

16:23 EDT Artisan Partners reports AUM as of August 31 $136.5B - Artisan Partners Asset Management reported that its assets under management as of August 31 totaled $136.5B. Separate accounts accounted for $73.3B of total firm AUM, while Artisan Funds and Artisan Global Funds accounted for $63.2B.

16:20 EDT AssetMark reports platform assets of $68B at the end of August, up 19.1% - AssetMark Financial Holdings released its "AssetMark Monthly Knowledge" Report. Company highlights for the month of August 2020 include: Platform assets of $68B at the end of August, up 19.1% year-over-year. Net flows were $54M in the month of August, up 6.7% year-over-year.

16:18 EDT Regional Management sees 'rebounding loan demand', August originations up 34% - The company states: "As of August 31, 2020, our credit profile remains stable, demand for our loan products continues to rebound, our balance sheet remains strong, and we maintain access to ample liquidity to fund our business operations and growth. Our proven operating model and financial strength enable us to continue to provide our customers with responsible and affordable credit solutions as the COVID-19 pandemic persists. As of August 31, 2020, our 30+ day contractual delinquency rate was 4.6%, compared to 4.5% as of July 31, 2020 and 4.8% as of June 30, 2020. Our 30+ day contractual delinquency totaled $47.8 million as of August 31, 2020, compared to $46.3 million as of July 31, 2020 and $49.5 million as of June 30, 2020. Demand for our loan products has continued to recover, with total originations increasing to $105.8 million in August, up 34% from $79.0 million in June. Our branch originations rose 21% to $80.8 million in August from $67.0 million in June. Our direct mail marketing campaigns and digital channels produced $24.9 million of originations in August, an increase of $12.9 million, or 108%, from June. Because September is typically a slower month for originations, we anticipate fewer branch, direct mail, and digital originations in September than in August."

16:15 EDT Virtus Investment reports preliminary total AUM $118.2B as of August 31

16:14 EDT Sol-Gel Technologies NDA for Epsolay accepted for filing by FDA - Sol-Gel Technologies announced that its new drug application, or NDA, for Epsolay, an investigational proprietary topical cream for the treatment of inflammatory lesions of rosacea, containing 5% encapsulated benzoyl peroxide, has been accepted for filing by the FDA. The Prescription Drug User Fee Act, or PDUFA, goal date assigned by the FDA for Epsolay is April 26, 2021. The NDA filing is based on two positive, identical Phase 3 randomized, double-blind, multicenter, 12-week, clinical trials that evaluated the safety and efficacy of Epsolay compared to vehicle in patients with papulopustular rosacea.

16:12 EDT AT&T CFO sees limited visibility on extent, duration of COVID impact - The company states: "John Stephens, CFO of AT&T Inc, spoke recently at the Bank of America Securities 2020 Media, Communications & Entertainment Conference where he provided an update to shareholders. Confident in ability to generate strong cash flows. Stephens said that the company continues to have limited visibility into the extent and duration of the impact of COVID and resulting government actions on the economy. In addition, while WarnerMedia continues to be impacted in areas such as the timing of theatrical releases as well its production schedule, the resumption of sports is expected to shift the timing of advertising revenues and costs into the third quarter from the second quarter. Despite these fluid dynamics, Stephens reiterated that AT&T remains confident in its ability to generate strong cash flows given the resiliency of wireless and broadband services and continued demand for business connectivity. Stephens said the wireless market remains very competitive but that AT&T continues to see benefits from its investment in significantly improving network capacity over the past few years. HBO Max traction continues. AT&T is pleased with the initial success of HBO Max, including its activation growth and solid levels of viewer engagement. The company continues to see weekly viewing hours for HBO Max that are significantly higher than for HBO Now."

16:09 EDT Oracle up approximately 4% to $59.66 after Q1 results beat estimates

16:07 EDT ICF International awarded $100M in Head Start contracts - ICF was recently awarded one new and four re-compete contracts to support Head Start programs across 18 states and the District of Columbia. The contracts, which were awarded by the Department of Health and Human Services, Administration for Children and Families, have a total combined value of over $100M and each has a term of five years, including one 11-month base and four 12-month options. Under the contracts, ICF will provide training and technical assistance to improve services to Head Start grantees to enable them to promote school readiness of children under 5 from low-income families.

16:05 EDT Mesa Air reports 18,747 block hours in August 2020 - Mesa Airlines reported 18,747 block hours in August 2020, a 52.1 percent drop from August 2019 as a result of reduced schedules during the COVID-19 pandemic. The company also reported a controllable completion factor of 100 percent and 99.97 percent for its American and United operations, respectively.

16:04 EDT Oracle CEO says 'Q1 was fantastic' - "Q1 was fantastic with total revenue beating guidance by more than $150 million, and non-GAAP earnings per share beating guidance by $0.07," said Oracle CEO, Safra Catz. "Our cloud applications businesses continued their rapid revenue growth with Fusion ERP up 33% and NetSuite ERP up 23%. We now have 7,300 Fusion ERP customers and 23,000 NetSuite ERP customers in the Oracle Cloud. Our infrastructure businesses are also growing rapidly as revenue from Zoom more than doubled from Q4 last year to Q1 in this year. I have a high level of confidence that our revenue will accelerate as we move on past COVID-19." "I believe that the Oracle Cloud offers better Infrastructure-as-a-Service (IaaS) technology than any other cloud vendor," said Oracle Chairman and CTO, Larry Ellison. "The really good news here is that I'm not the only one who thinks that's true. Here is an approved quote from IDC."

16:03 EDT Oracle reports Q1 Cloud license and on-premise license revenues 886M

15:54 EDT Google expands protections for search features, including autocomplete - The company said in its The Keyword blog post, "We have policies for what can appear in Search features like featured snippets, lists or video previews that uniquely highlight information on the search results page. One notable example is Autocomplete, which helps you complete your search more quickly. We have long-standing policies to protect against hateful and inappropriate predictions from appearing in Autocomplete. We design our systems to approximate those policies automatically, and have improved our automated systems to not show predictions if we detect that the query may not lead to reliable content. These systems are not perfect or precise, so we enforce our policies if predictions slip through.We expanded our Autocomplete policies related to elections, and we will remove predictions that could be interpreted as claims for or against any candidate or political party. We will also remove predictions that could be interpreted as a claim about participation in the election-like statements about voting methods, requirements, or the status of voting locations-or the integrity or legitimacy of electoral processes, such as the security of the election. What this means in practice is that predictions like "you can vote by phone" as well as "you can't vote by phone," or a prediction that says "donate to" any party or candidate, should not appear in Autocomplete. Whether or not a prediction appears, you can still search for whatever you'd like and find results. Information online is constantly changing-as are the things people search for-so continuing to deliver high-quality information is an area of ongoing investment. We've made great strides and built upon successful improvements to our systems, and we'll continue to look for new ways to make Search and News as reliable and helpful as possible, no matter what you're looking for." Reference Link

15:19 EDT Ubisoft unveils 'Prince of Persia: Sands of Time' remake, coming in January 2021 - At its UbiForward event, Ubisoft (UBSFY) announced that a full remake of "Prince of Persia: The Sands of Time," a game which originally came out in 2003, will be coming to PlayStation 4 (SNE), Xbox One (MSFT), and PC on January 21, 2021. Reference Link

14:45 EDT First Majestic Silver trading halted, news pending

14:29 EDT North American rail traffic increased 7.6% in the week ended August 29 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending September 5.Total carloads for the week ending September 5 were 222,298 carloads, down 6.9% percent compared with the same week in 2019, while U.S. weekly intermodal volume was 287,339 containers and trailers, up 24.8% compared to 2019.North American rail volume for the week ending September 5, on 12 reporting U.S., Canadian and Mexican railroads totaled 319,928 carloads, down 4.8% compared with the same week last year, and 377,841 intermodal units, up 20.8% compared with last year. Total combined weekly rail traffic in North America was 697,769 carloads and intermodal units, up 7.6%. North American rail volume for the first 36 weeks of 2020 was 22,822,410 carloads and intermodal units, down 10.5% percent compared with 2019. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Genesee & Wyoming (GWR), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP). Reference Link

13:47 EDT Five Holland America Line ships set to 'explore Europe' in 2021 - From Greenland to Greece and Iceland to Israel, five Holland America Line ships are set to "explore the cultural kaleidoscope of Europe" in 2021, according to the company. The brand's collection of vessels crossing the pond includes Rotterdam, which is slated to debut at the height of the summer Europe season. Joining the fleet's new flagship will be Nieuw Statendam, Westerdam and Zuiderdam, putting two Pinnacle Class ships in the region. Zaandam heads to Europe on the popular "Voyage of the Vikings" itinerary in July. From April through November, the five ships will offer itineraries ranging from seven to 35 days, as well as longer Collectors' Voyages up to 29 days. In addition to transatlantic crossings between Fort Lauderdale, Florida, and Europe, the ships will visit the Baltic, British Isles, French and Spanish rivieras, Iberian Peninsula, Mediterranean and Northern Europe including Greenland, Iceland, Norway and the North Cape. Holland America Line is a division of Carnival.Reference Link

13:16 EDT Tanger Outlets to begin 2020 holiday season early, close on Thanksgiving Day - Tanger Factory Outlet Centers announced that the company will close on Thanksgiving Day amid the COVID-19 pandemic. To meet the needs of customers changing lives this holiday season, Tanger is enhancing holiday shopping and kicking off the season on November 1st. Tanger and its retail partners will start offering the best deals of the season earlier than ever, giving everyone a chance to shop when they want and how they want, to make shopping hassle free and festive for all. Extended hours will also begin the first weekend in November and continue throughout the holiday. This year, Tanger has expanded its services to make shopping even more convenient by offering three ways to shop, which include in-person shopping all of Tanger's centers, multiple curbside pick-up locations throughout each property, and its exclusive Virtual Shopper Concierge program.

12:21 EDT Northern Dynasty says J Capital report 'fatuous, flimsy' and 'self-serving' - Northern Dynasty Minerals responded to a report issued by Beijing-based short seller J Capital Research on September 9, calling it "fatuous, flimsy and fundamentally self-serving," as well as "typical of such efforts to profit by destroying the value of honest shareholders' investments." Northern Dynasty President and CEO Ron Thiessen said: "We have heard and responded to the same baseless claims in JCap's 'research' report countless times since they were initially levelled by New York-based 'short-and-distort' firm Kerrisdale Capital back in 2017. Financial markets weighed and dismissed Kerrisdale's self-serving arguments then, and we are confident they will do so even more swiftly this time with these unoriginal allegations coming out of China." Thiessen noted that the allegations in the Kerrisdale report formed the basis of several derivative shareholder actions against Northern Dynasty, which were ultimately dismissed by the courts for failure to state a cause of action. JCap's report, entitled "Pretend & Extend: The No-Return Deposit," claims that Northern Dynasty's 100%-owned Pebble copper-gold-molybdenum-silver-rhenium project in southwest Alaska will lose money, that capital costs have been underestimated and that the project's proposed mining plan intentionally targets low-grade portions of the deposit. Less than four months ago, JCap levelled similar accusations against Alaska's other late-stage mineral prospect - the Donlin Gold project (co-owned by Barrick and Novagold) - leading to a civil action lawsuit for defamation being brought against the firm, said Northern Dynasty. "We will take an appropriate amount of time to review the report and the market's reaction to it, if any, as well as our options for protecting the company and our shareholders from these spurious claims," Thiessen said, adding the company may choose to issue a comprehensive response or "may simply ignore what is intrinsically a self-serving attempt to profit by creating panic in the marketplace." Thiessen said, according to a press release from the company, that he believes "other parties engaged in market manipulation and short-selling have conspired to cost Northern Dynasty shareholders, large and small, some $500M in recent months. He said there is little the company can do to prosecute or counter these illegal activities other than continuing to advance the Pebble Project toward final permitting, construction and profitable operations."

12:10 EDT Nikola founder says will issue 'detailed report' to address 'false claims' - Trevor Milton, the founder and Executive Chairman of Nikola, tweeted: "Cowards run, leaders stay and fight for integrity. Hindenburg is only making people love us more for trying to destroy us. It will take the rest of the day to address the one sided false claims, but I will put out a detail report to address it. In the meantime, troll on" His tweet follows the release earlier this morning of a short report in which Hindenburg Research accused the company and Milton of fraud. Reference Link

12:02 EDT AMC's 'The Walking Dead' to end with expanded eleventh season - AMC Networks announced yesterday that "The Walking Dead" will end with an expanded two-year eleventh season that will span 24 episodes. With the previously announced six extra season 10 episodes scheduled for early next year, there are 30 remaining episodes that will run through late 2022, AMC said in a statement. The original series will be followed by a greenlit spin-off focused on the Daryl Dixon and Carol Peletier characters, which will premiere in 2023, AMC added. AMC is also working with Scott Gimple to develop a new "Tales of the Walking Dead" series, an episodic anthology.

12:00 EDT K12 falls -15.0% - K12 is down -15.0%, or -$5.05 to $28.71.

12:00 EDT Companhia Brasileira de Distribuicao rises 13.6% - Companhia Brasileira de Distribuicao is up 13.6%, or $1.59 to $13.27.

12:00 EDT RH rises 23.0% - RH is up 23.0%, or $73.89 to $394.97.

11:28 EDT Novan assessing ability to inhibit replication mechanism of SARS-COV-2 - Novan said via Twitter that it is assessing in vitro the ability of its proprietary NITRICIL technology to inhibit the replication mechanism of SARS-COV-2. Reference Link

11:14 EDT Navistar confirms receipt of revised proposal from Traton - Navistar confirmed that it has received a revised proposal from TRATON SE to acquire Navistar for $43 per share in cash. The company said, "Navistar's Board of Directors and management team are committed to exploring all avenues to maximize value. Consistent with its fiduciary duties, the Board will carefully review the revised proposal from TRATON in consultation with its advisors to determine the course of action that it believes is in the best interests of the Company and its stakeholders. Navistar shareholders do not need to take any action at this time, and there is no assurance that any transaction with TRATON will occur or be consummated. Navistar does not intend to make any additional comments regarding the proposal unless and until it is appropriate to do so, or a formal agreement has been reached."

10:00 EDT Pros Holdings falls -8.5% - Pros Holdings is down -8.5%, or -$2.99 to $32.33.

10:00 EDT GameStop falls -11.8% - GameStop is down -11.8%, or -87c to $6.48.

10:00 EDT Navistar rises 17.9% - Navistar is up 17.9%, or $6.40 to $42.24.

09:51 EDT Portland General Electric falls -5.8% - Portland General Electric is down -5.8%, or -$2.21 to $35.93.

09:51 EDT GameStop falls -10.4% - GameStop is down -10.4%, or -76c to $6.59.

09:51 EDT Navistar rises 18.9% - Navistar is up 18.9%, or $6.78 to $42.62.

09:46 EDT Verb Technology acquires SoloFire platform for heatlhcare sales enablement - VERB Technology announced that it has completed the acquisition of SoloFire, provider of a sales enablement platform for the healthcare industry. "We are delighted to welcome SoloFire to the VERB family," said VERB CEO Rory J. Cutaia. "SoloFire's natural, strategic fit with VERB's portfolio of sales enablement solutions has made this a compelling acquisition for us. Through this accretive acquisition, the combined offering will empower medical companies to continue to effectively build stronger relationships with customers and prospects in a unique and engaging manner, driving sales conversion rates, especially during a challenging period marked by pandemic fears and restrictions."

09:39 EDT CleanSpark announces multi-unit switchgear contract - CleanSpark announced that it has received a contract for multiple units of its intelligent switchgear equipment from a long-term energy development partner based in Houston, TX. The most recent orders are for five Switchgear units, three of which will be installed on a surface water pumping station in the Houston area. The two additional units were ordered for a Texas-based grocery chain that has CleanSpark Switchgear currently deployed on several of their locations. The microgrids that incorporate the intelligent ATS solutions not only monitor increasing demand intervals from the utility in order to optimize energy consumption, but also provide a reliable back-up energy solution. This 'baked-in' resiliency keeps the site operational even during extended utility outages caused by events such as hurricanes. The latest orders are expected to add additional revenue that CleanSpark will recognize during the coming quarter. CleanSpark has shipped in excess of $7.4M in Switchgear during the current fiscal year.

09:29 EDT CTO Realty Growth announces sale of property in Florida for approx. $2.5M - CTO Realty Growth announced the closing of the sale of a property located in Jacksonville, Florida leased to PDQ, for a sales price of approximately $2.5M, reflecting an exit cap rate of approximately 6.1%. The property is currently under a ground lease to PDQ with 6.9 years remaining on the initial term of the lease. The proceeds are expected to be part of a future Section 1031 like-kind exchange. The Company estimates a gain on the sale of approximately $128,000, or 2c per share, after tax. Including this transaction, the Company has over $12M of proceeds held in 1031 restricted cash accounts. Year to date, the Company has completed the sale of seven single-tenant net lease properties and one multi-tenant retail property, for an aggregate sales price of more than $51M.

09:28 EDT Capstone Turbine signs 5-year long-term FPP service contract - Capstone Turbine said in a release, "Capstone Turbine announced that Optimal Group Australia, Capstone's exclusive Australian distributor, recently signed a 2 Megawatt 5-Year Factory Protection Plan, or FPP, with a remotely located Oceana-based mineral water bottling facility. The project uses two stand-alone C1000 Signature Series (C1000S) one-megawatt microturbine systems running on clean-burning propane as a primary baseload power source for a mineral water bottling facility located on a remote off-grid island location. The site will have up to 8 MW's of power demand, and a portion of this demand is currently met with diesel fuel generators running in parallel with the clean and green Capstone microturbines. The site was recently upgraded with a new 50-ton propane tank. This site's commissioning was initially delayed by the COVID-19 pandemic, which first hit in the APAC (Asia Pacific) region, but this project is now moving forward again."

09:26 EDT Medexus reports Health Canada approval of Gleolan four use in surgical resection - Medexus announces that on September 9, 2020, it received a Notice of Compliance from Health Canada granting approval for the marketing of Gleolan in Canada. Gleolan is a 5-aminolevulinic acid hydrochloride powder for oral solution, and is indicated as an adjunct for the visualization of malignant tissue during surgery in patients with Grades III or IV gliomas as classified by the World Health Organization. Gleolan is an imaging agent that makes high-grade gliomas fluoresce under blue light, assisting neurosurgeons to better visualize these gliomas for more complete removal. After administration, areas within the tumour glow pink or red, and healthy brain tissue appears blue when exposed to a special blue light during surgery. There are currently no other optical imaging agents approved in Canada for the purpose of visualization of malignant tissue during glioma surgery. A pivotal Phase III study, published in The Lancet Oncology Medical Journal, has shown that use of Gleolan during brain tumour surgery has nearly doubled the rate of achieving a complete resection of the tumour, which in turn has resulted in a doubling of the number of patients without progression of their brain cancer six months after surgery. The study reported complete resection of malignant brain tumour tissue in 65% of patients receiving Gleolan compared to 36% of patients in the study's control arm. Six-month progression-free survival was achieved in 41% of patients receiving Gleolan compared to 21% of patients who were operated on without the use of the drug (difference between groups 20%. Health anada had previously granted Medexus authorization to distribute Gleolan in Canada under the Special Access Programme, which provides healthcare practitioners with access to non-marketed drugs to treat patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. In March 2020, the Quality business unit at Ontario Health, based on guidance from the Ontario Health Technology Advisory Committee, recommended publicly funding Gleolan for guiding maximal surgical resection of high-grade gliomas, which was conditional on Health Canada approval of the technology. The Company is awaiting final funding approval from the Ontario Ministry of Health.

09:18 EDT CHF Solutions announces key takeaways from physician-led webinar - CHF Solutions announced key takeaways from a recent webinar, where Dr. John Jefferies discussed the use of precision medicine for the treatment of fluid overload in heart failur patients, including alternatives to diuretics, such as ultrafiltration using the Aquadex SmartFlow system. Clinically important observations made by Dr. Jefferies during the webinar include: The impact of fluid overload on HF patients is significant. 90% of HF hospitalizations are due to signs and symptoms of fluid overload. Common fluid overload treatment approaches such as diuretics are associated with mixed outcomes and adverse events. Studies have shown 42% of acutely decompensated HF patients either return to the emergency room, are re-hospitalized or die within 60 days of hospital discharge, regardless of diuretic strategy. Ultrafiltration is an effective treatment strategy for patients with HF. When compared to diuretics, there is a 53% reduction in the risk of rehospitalization among HF patients receiving ultrafiltration. The use of ultrafiltration after cardiac surgery has been shown to improve cardiac performance, reduce the duration of assisted ventilation5 and can reduce the need for blood transfusions. Dr. Jefferies also discussed Aquadex-specific considerations and recommendations in regard to venous access, anticoagulation, ultrafiltration rate and Hematocritand SV02 monitoring. Access this information and a white paper analysis by watching the webinar replay available on the company website and on CHF Solutions' YouTube page. Dr. Jefferies' presentation will be a part of the company's offerings at the 24th Annual Scientific Meeting of the Heart Failure Society October 3-5, 2020.

09:17 EDT DraftKings appoints Erik Bradbury as CAO - DraftKings announced that Erik Bradbury has been named the Company's chief accounting officer and principal accounting officer effective September 10, 2020, reporting to CFO Jason Park. Bradbury was most recently a Partner with Ernst & Young and served as a Professional Accounting Fellow at Financial Executives International. Bradbury will oversee DraftKings' corporate accounting functions including SEC and regulatory reporting, operational accounting, accounting policy, and development of relevant accounting positions.

09:12 EDT Philip Morris sees FY20 effective tax rate approx. 22%, at lower end of view - Sees lack of near-term recovery in PMI's duty-free business given the uncertain outlook for global travel, with current dynamics persisting at least through the fourth quarter, compared to the third quarter assumed previously.

09:10 EDT Vertex Pharmaceuticals completes Phase 3 Trikafta study - Vertex Pharmaceuticals announced the company has completed a global Phase 3 study of Trikafta in children ages six through 11 years old with cystic fibrosis, or CF, who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation, and based on the results will submit a supplemental new drug application, or sNDA, to the FDA in Q4, with additional global regulatory submissions to follow. The 24-week global Phase 3 open-label study evaluated the safety and efficacy of Trikafta in 66 children ages six through 11 years old who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation. The primary endpoint of the study was safety and tolerability, and the results showed that Trikafta was generally well tolerated and the safety data were consistent with those observed in previous Phase 3 studies. In addition, clinically meaningful improvements were seen across multiple secondary efficacy endpoints, including improvements in percent predicted forced expiratory volume in one second, or ppFEV1, sweat chloride, Cystic Fibrosis Questionnaire Revised respiratory domain score, body mass index and other measures through 24 weeks of treatment. The study showed the benefit-risk profile of Trikafta in children with CF ages 6 through 11 years old was similar to that seen in people with CF ages 12 and older in the Phase 3 studies which have supported approval. Based on the results, Vertex will submit an sNDA to the U.S. FDA in Q4, with additional global regulatory submissions to follow.

09:09 EDT UPS appoints Eva Boratto, Wayne Hewett to board of directors - UPS (UPS) announced the election of Eva Boratto, CFO and EVP of CVS Health (CVS) and Wayne Hewett, former CEO of Klockner Pentaplast Group and of Arysta LifeScience Corporation, to the UPS Board of Directors, effective immediately.

09:07 EDT UnitedHealth, Canopy Health introduce new health plan in Northern California - UnitedHealthcare and Canopy Health have introduced a new health plan that offers consumers in Northern California customer support as well as the opportunity to save up to 25% on premiums. As the latest addition to a portfolio of health plans the two organizations have launched together, the California Doctors Plan provides access to health care for people with employer-sponsored health coverage in nine Bay Area counties: Alameda, Contra Costa, Marin, San Francisco, San Mateo, Santa Clara, Santa Cruz, Solano and Sonoma. This plan is the result of a collaboration between UnitedHealthcare and Canopy Health. Canopy Health is an accountable care network of providers and health systems in the Bay Area. UnitedHealthcare and Canopy Health expanded their relationship earlier this year with the launch of the UnitedHealthcare Canopy Health Medicare Advantage plan.

09:06 EDT Seanergy Maritime announces open-market stock purchase plan up to 500,000 shares - Seanergy Maritime announced today that its Chairman and CEO Stamatis Tsantanis, intends to purchase an aggregate of up to 500,000 common shares of the Company in the open market. In addition, for at least the next 12 months, Mr. Tsantanis does not intend to sell any newly acquired shares of the Company or any of the shares he currently holds, which were acquired in previous years. In addition, it is the Company's intention not to initiate any public equity offerings until March 2021, nor to implement any reverse stock splits prior to that date. Lastly, regarding the Class E warrants that were issued pursuant to the Company's $25.0 Million underwritten public offering that closed on August 20, 2020, the Company's Board of Directors does not intend to exercise its option, pursuant to the terms of the warrants, to adjust the original exercise price of $0.70 per share downwards. Notwithstanding the Company's current intentions, the Board of Directors will continue to evaluate all available strategic alternatives, which may include stock issuances to the Company's creditors as a means of addressing maturing debt instruments, based on market conditions and other factors which may arise in the future.

09:05 EDT Brink Biologics announces licensing agreement with Fresenius - Brink Biologics said in a release, "Brink Biologics, a NantKwest affiliate and exclusively-licensed distributor of NantKwest's proprietary off-the-shelf NK-92 natural killer cells in certain fields, announces the licensing of its next-generation natural killer-based bioanalytical testing solution to Fresenius Kabi SwissBioSim GmbH, or Fresenius, a Switzerland-based global healthcare company focusing on autoimmune diseases and oncology. Brink Biologics offers a variety of GLP and research-grade NK-92 based cell lines as part of its Neukopanel portfolio of products for laboratory testing applications. Neukopanel includes discovery, translational and developmental research as well as commercial lot release testing of clinical products. Brink products are utilized widely by large pharmaceuticals and biotechnology companies to support products ranging from anti-viral and dendritic cell vaccines, therapeutic monoclonal antibodies and biosimilars, bi- and tri-specific fusion proteins, cytokines, natural killer cell checkpoint inhibitors and other biologic products."

09:05 EDT Baidu launches Apollo Go Robotaxi service in Beijing - Baidu launched the Apollo Go Robotaxi service in Beijing, becoming the first company to allow people in China's capital to use robotaxis. The service encompasses the largest total area and longest road network of about 700 kilometers for a manned autonomous driving test area in China, with nearly 100 pick-up and drop-off stations. Apollo Go will launch 40 vehicles. Beijing users can experience the Apollo Go Robotaxi service after registering on Baidu Maps or the Apollo website. In addition to Beijing, Apollo Go has opened services to the public in cities including Changsha and Cangzhou. After eight months of small-scale manned testing, the Baidu Apollo robotaxi fleet has completed road tests totaling 519,000 kilometers in Beijing and obtained permission to enter the next stage: opening up to the general public.

09:02 EDT Seelos Therapeutics granted additional US patent for Trehalose - Seelos Therapeutics has received a Notice of Allowance from the USPTO. The allowed claims cover a method of using trehalose to treat several neurodegenerative conditions including spinocerebellar ataxia, spinal and bulbar muscular atrophy, dentatomral-pailidoluyssan atrophy, Pick's disease, corticobasaldegeneration, progressive supranuclear palsy, and frontotemporal dementia.

08:57 EDT LVMH to file lawsuit against Tiffany over management during crisis - LVMH (LVMUY) announced its intention to file a lawsuit against Tiffany (TIF). The company said in a statement: "LVMH was surprised by the lawsuit filed by Tiffany against the Group in the Court of Chancery of the State of Delaware. LVMH considers that this action is totally unfounded. It has clearly been prepared by Tiffany a long time ago and communicated in a misleading way to shareholders and is defamatory. LVMH will defend itself vigorously. The long preparation of this assignment demonstrates the dishonesty of Tiffany in its relations with LVMH. This action is essentially based on the accusation by Tiffany that LVMH failed to take the reasonably necessary steps to obtain the various regulatory authorities' approvals in a timely way. This accusation has no substance and LVMH will demonstrate this to the Delaware Court. On this matter, the filing in Brussels will take place, as expected, in the following days and this is simply the result of the planning fixed by the European Commission, about which Tiffany is completely aware. It is legitimate to expect this authorization will be obtained in October. The LVMH Board, besides the elements already raised, had the opportunity to examine the current economic situation of Tiffany and its management of the crisis. It noted that the first half results and its perspectives for 2020 are very disappointing, and significantly inferior to those of comparable brands of the LVMH Group during this period. LVMH will be therefore led to challenge the handling of the crisis by Tiffany's management and its Board of Directors. LVMH considers, among other things, that this period is impacted by a Material Adverse Effect, that Tiffany did not follow an ordinary course of business, notably in distributing substantial dividends when the company was loss making and that the operation and organization of this company are not substantially intact. LVMH therefore confirms that the necessary conditions for the conclusion of the acquisition of Tiffany are not fulfilled."

08:54 EDT Aditx Therapeutics appoints Drew Pinksy as senior advisor to AditxtScore - Aditx Therapeutics announced that it has appointed Dr. Drew Pinsky as Senior Advisor, AditxtScore, effective September 1, 2020. Drew, a practicing physician, internist, and an addiction medicine specialist, will advise on the development of AditxtScore platform, and its various potential applications including possibly scoring immunity to COVID-19 and other infectious diseases, as well as autoimmune disorders such as Type I Diabetes. And as a well-known American media personality, Drew will act as brand ambassador as he advises on the overall marketing and deployment strategies of AditxtScore. He will also assist in the planning and introduction of the platform and its applications for the medical and consumer markets.

08:47 EDT CV Sciences launches CV Defense daily immune support - CV Sciences announced its continued expansion into condition specific dietary supplements with the launch of CV Defense, the second of several products to be launched under its new Immunity product line, following the launch of CV Acute in August. The expansion of CV Sciences' non-CBD Immunity product line will continue to open markets and sales channels for the Company, including major e-commerce retailers not currently accessible by CBD-based products. CV Defense is now available on CV Sciences' website and will be available next week on Amazon.com. CV Defense is a clinically supported immune formula that provides effective daily support for barrier immunity, innate immunity, and adaptive immunity. CV Sciences' team of doctors and scientists formulated this product with specific intent - to fortify daily immune health. Based on PEA, a clinically researched ingredient to support the immune system, and combined with time-tested nutrients and botanicals, including vitamins A and D, the minerals selenium and zinc, and an Organic Reishi Mushroom Extract with concentrated beta-glucans, CV Defense incorporates unique ingredients able to optimize immune response.

08:47 EDT Newmont recommends holders reject 'mini-tender' offer by TRC Capital - Newmont said in a release, "Newmont has received notice of an unsolicited 'mini-tender' offer by TRC Capital Investment Corporation to purchase up to 2M (approximately 0.25 percent of the outstanding) shares of common stock of Newmont at $63.75 per share. This offering price is 4.44% BELOW the $66.71 per share closing price of Newmont shares on August 28, the day before the offer. TRC has made its offer subject to numerous conditions and has stated that it may terminate or amend its offer if, among other things, it does not obtain sufficient financing on terms satisfactory to it or there are certain decreases in the value of the shares. Newmont recommends that: Stockholders who have not responded to the TRC offer take no action because the offer is at a price below the current market price for Newmont shares and is subject to numerous conditions; and Any stockholders who have tendered shares to the TRC offer withdraw those shares by providing the written notice described in the TRC offering documents before the expiration of the offer, which currently is scheduled for 12:01 a.m., New York City time, on September 30. TRC has made many similar mini-tender offers for shares of other companies. Mini-tender offers, such as this one, are offers to acquire less than five percent of a company's outstanding shares and avoid many of the investor protections afforded for larger tender offers, including the filing of disclosure and other tender offer documents with the SEC, and other procedures required by U.S. securities laws. The SEC has expressed serious concerns and cautioned investors about these offers, noting that 'some bidders make mini-tender offers at below-market prices, hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.'"

08:42 EDT Franklin Street announces new leasing activity in Texas portfolio - Franklin Street announced new leasing activity in its Texas portfolio totaling approximately 55,000 square feet to date during Q3. In its Dallas portfolio, the company signed leases with Compassus, Homebridge Financial Services, Trinity Highway Products, CX Institutional and Schell Cooley. In our Houston portfolio, we signed leases with Ranger Energy Services Inc. and Lord Downing.

08:39 EDT Manitex announces new orders for fleet of Valla electric cranes valued at ~$2.5M - Manitex said in a release, "Manitex announced that it has been awarded a contract by Colle Rental & Sales, of Sittard, Netherlands, for Valla electric cranes, valued at approximately $2.5M. The new order represents the largest single Valla order in the company's 75-year history. The initial order is for more than 30 cranes that will join Colle's rental fleet in the second half of 2020, and includes a number of the company's electric, zero-emissions models, the Valla V80R, V110R, V36 R and V200R. The order additionally provides the customer with the option to purchase approximately $1.9M of new Valla cranes in 2021."

08:36 EDT Datasea signs six agreements to implement Smart Information Service System - Datasea has entered into service agreements involving its Smart Information Service System with Shenzhen Linghang Haocheng Education Technology Co., an education training company, Shenzhen Weisou Technology Co., an application operator, and four gas stations in Shenzen and Shanwei, all located on the Guangdong province.

08:34 EDT PDL BioPharma to complete Lensar spin-off on October 1 - PDL BioPharma has approved the separation of Lensar, a majority owned subsidiary of PDL, from PDL in the form of a dividend involving the distribution of all outstanding shares of Lensar common stock owned by PDL to holders of PDL common stock. Lensar common stock is expected to be distributed on October 1 to PDL stockholders of record as of September 22. PDL stockholders will receive 0.075879 shares of Lensar common stock for every one share of PDL common stock held by such holders - after giving effect to a one-for-nine reverse split of LENSAR's common stock effected on September 9 -. Immediately after the distribution is completed, Lensar will be an independent, publicly traded company, and "regular-way" trading of Lensar's common stock will begin the first trading day after the completion of the distribution. The Lensar stock is expected to be listed on Nasdaq under the symbol "LNSR." No action is required by PDL stockholders to receive the shares of Lensar common stock in the distribution. Fractional shares of LENSAR common stock will not be distributed, but aggregated and sold in the public market by the transfer agent. The aggregate net proceeds of these sales will be distributed ratably as cash payments to the stockholders who would otherwise have received fractional interests. Lensar expects its common stock to begin trading on a "when-issued" basis shortly before the September 22 record date under the ticker "[LNSRV]." The completion of the distribution is subject to the satisfaction or waiver of a number of conditions, including the declaration by the SEC of the effectiveness of the Form 10, the LENSAR common stock being accepted for listing on the Nasdaq exchange and final approval by the PDL Board of Directors that the distribution remains in the best interest of PDL and its stockholders and that the distribution is still advisable.

08:33 EDT CVS Health: COVID-19 tests available for children 12, older at drive-thru sites - As part of its comprehensive effort to increase access to COVID-19 testing in order to help slow the spread of the virus, CVS Health announced that children age 12 years and older are eligible for testing at the more than 2,000 test sites located at select CVS Pharmacy drive-thru testing locations, starting Friday, September 11. In addition, more than 120 new test sites will open Friday at CVS Pharmacy drive-thru locations across the country. In recent weeks, CVS Health has expanded its network of independent third-party lab partners in an effort to help improve turnaround time for the delivery of test results. As a result, the majority of test results from specimens collected at CVS test sites across the country will generally be available within 2 - 3 days.

08:30 EDT Citi CEO Michael Corbat announces plans to retire Feb. 2021

08:25 EDT Centogene expands COVID-19 testing capacity at Frankfurt Airport - Centogene announced that the company has expanded its SARS-CoV-2 testing capacity at Frankfurt Airport to continue supporting safe travel for passengers as international borders open amid the new normal/ Passengers flying to or from Frankfurt Airport with Lufthansa will be able to perform the test at the new expanded sampling center conveniently located near the main terminal. This can either be completed the day before traveling or with a fast track solution the same day before departure. All results are delivered to the passenger via a secure digital platform. Additionally, passengers can opt into an ID confirmation service, assuring authorities that the passengers' identities correspond with the test results. CENTOGENE's Frankfurt COVID-19 Testing Facility will also be available to anyone wishing to get tested, whether they are travelling or not. The Company believes that a fully digitized system, which now includes integration with the Corona-Warn-App, is the only way to efficiently provide testing that reaches travelers in a way that is easily accessible. The entire process is supported by an innovative digital workflow, which allows customers to easily register, order, and download reports via their smartphone or computer.

08:21 EDT Konica Minolta introduces Exa Gateway platform for remote reading - Konica Minolta Healthcare is introducing Exa Gateway, a cost-effective platform for secure remote reading that connects hospital radiology departments, radiology practices and teleradiologists through technology and services. Many radiology imaging facilities are not staffed to handle the increased volume of studies and are seeking ways to supplement reading services to avoid lengthy report turn-around-times and further disruptions to patient care. It is anticipated that the use of teleradiology and remote reading services will continue to be increasingly utilized post-pandemic, particularly with a projected shortage of tens of thousands of radiologists in the US by 2025. By utilizing a facility's existing PACS investment, Exa Gateway minimizes costs, streamlines connectivity and enables teleradiologists to use their current PACS worklist and viewer with which they are already familiar. There is no additional strain on existing IT staff and resources. Hospital radiology departments can add to or start teleradiology services, providing the flexibility to manage fluctuating volumes. Radiology practices can implement remote reading capabilities with access to teleradiologists to handle overflow of studies or provide overreads and sub-specialty interpretations, enhancing their service to referring physicians and patients. Exa Gateway can be configured for both existing Exa customers and non-Exa users.

08:16 EDT Bionano Genomics announces adoption of Saphyr at European pediatric hospitals - Bionano Genomics announced that its Saphyr system has been adopted through reagent-rental agreements by three renowned institutions in Spain, Italy and France: Nino Jesus University Children's Hospital in Madrid; Ospedale Pediatrico Bambino Gesu in Rome; and Necker-Enfants Malades Hospital in Paris. The three children's hospitals aim to assess Saphyr's potential for use in diagnosing childhood leukemias versus current standards of care, including karyotyping, chromosomal microarray and FISH.

08:14 EDT Aaron's up 4% to $57.50 after raising Q3 guidance

08:13 EDT Nikola down 2% in pre-market after Hindenburg alleges fraud - In pre-market trading, shares of Nikola are down 98c, or 2.3%, to $41.39 after short-selling focused firm Hindenburg Research accused the company and its founder, Trevor Milton, of fraud.

08:11 EDT Equinix investigating security incident involving ransomware on internal systems - In a regulatory filing, Equinix disclosed that it is currently investigating "a security incident we detected that involves ransomware on some of our internal systems. Our teams took immediate and decisive action to address the incident, notified law enforcement and are continuing to investigate. Our data centers and our service offerings, including managed services, remain fully operational, and the incident has not affected our ability to support our customers. Note that as most customers operate their own equipment within Equinix data centers, this incident has had no impact on their operations or the data on their equipment at Equinix. The security of the data in our systems is always a top priority and we intend to take all necessary actions, as appropriate, based on the results of our investigation."

08:09 EDT CTG says 'on track' to position company as 'premier global solutions provider' - CTG issued the following statement: "For the past several years, the CTG Board and management team have been implementing a plan to transform into a high-margin, solutions-centric business. We have made significant progress in this transformation and our strong performance trends over the past eighteen months are proof that our strategy is working. Despite the unprecedented and challenging global business environment, we delivered strong second quarter results with both revenue and non-GAAP operating profit increasing sequentially. These results are directly attributable to our team's dedication and the disciplined execution of our strategy, and contributed to CTG achieving our highest first half operating margin and non-GAAP earnings per share in six years. By continuing to shift our portfolio toward higher margin services and solutions, we will enhance the durability of our business model, improve operating leverage and position the Company to capitalize on opportunities for growth and value creation over the long-term. CTG's directors are actively engaged in overseeing the Company's transformation, and challenge the executive management team to deliver on our strategic objectives and create value for stakeholders. The CTG Board brings significant senior leadership experience and expertise in information technology, strategic planning, risk management and other areas relevant to the Company's strategy and operations. In the last three years the Board has added two new directors who bring fresh perspective, and whose diverse backgrounds add to the Board's deep bench of talent. The CTG Board reviews the Company's pay programs, including those for directors, to ensure they are competitive with our peers and reflect industry best practices. We continue to stand at the forefront of aligning executive and director compensation with performance and total shareholder returns. To that end, the Compensation Committee of the Board, with the support of an independent consulting firm, develops packages that include a significant amount of tailored, performance-based incentives. In January 2018, we eliminated cash compensation for non-employee directors in favor of providing compensation exclusively in CTG shares to directly align the interests of our non-employee directors to those of our shareholders. In addition, in 2017 and 2018 the Board awarded equity-based compensation for senior leadership that included grants and associated vesting solely based upon a 50% and 100% increase in CTG's share price. In both 2019 and 2020, a significant portion of the equity grants to the leadership team included performance targets that must be met before any vesting will occur. Based upon the most recent study performed by the Company's independent consultant, CTG directors are paid at the median as compared with similar sized companies, and other than a minor change to the chairman's fee for participation on the Nomination and Governance Committee, there have been no changes in Board fees since 2014. Prior to October 2014, the position of CEO and Chairman were combined in one position. In October 2014, a non-executive chairman was elected by the Board. The fees paid to the Chairman of the Board, totaling $100,000 annually, were a significant part of the increase in the Board's total compensation when comparing the 2015 Board fees with those from 2014. Our dynamic business generates solid and consistent free cash flow. In recent years, with the support of numerous CTG investors, the Company has developed a program to return excess capital to shareholders in a tax-free manner under a robust share repurchase authorization. We will continue to take steps to build on our momentum and position CTG to capitalize on the significant long-term growth opportunities in our served end markets. We are confident that our expanded solutions offerings during the second half of the year will advance our future growth opportunities and accelerate the achievement of our objectives, including generating substantial long-term value for CTG shareholders."

08:08 EDT Kohl's launches Adidas active collection with actress Zoe Saldana - Kohl's (KSS) and Adidas (ADDYY) announced a new collaboration with actress and activist Zoe Saldana to launch the adidas x Zoe Saldana collection of active apparel, footwear and accessories for women. Curated by Zoe Saldana herself, the trend-forward head-to-toe women's activewear collection includes tops, bottoms, jackets, footwear, bags and hats. The collection includes an array of pastel and colors, for all women, whether hanging out at home or exercising on-the-go, providing her plenty athleisure wardrobe options that will be available on Kohls.com and in select Kohl's stores beginning September 30. Kohl's will bring the adidas x Zoe Saldana collection to its millions of customers nationwide through a two-year partnership with Adidas.

08:07 EDT Satsuma: EMERGE trial data did not show statistically significant differences - Satsuma Pharmaceuticals announced topline results from its Phase 3 EMERGE efficacy trial of STS101 powder as an acute treatment for migraine. Although topline data showed numerical differences in favor of STS101 3.9 mg and 5.2 mg versus placebo on the pre-specified co-primary endpoints of freedom from pain and freedom from most bothersome symptom at two hours post-administration, these differences did not achieve statistical significance for either dosage strength. Both dosage strengths of STS101 did, however, demonstrate significant effects on both freedom from pain and most bothersome symptom by three hours post-dose and later time points. Both STS101 dosage strengths were well-tolerated in the EMERGE trial, with low adverse event rates and no serious adverse events reported. Further analysis of EMERGE trial data is ongoing, and Satsuma expects to provide a more detailed update on its business plans after these analyses are completed. As of June 30, 2020, the Company had cash, cash equivalents and marketable securities of $93.7 million.

08:05 EDT Papa John's signs development deal to open 49 new stores in Philadelphia area - Papa John's announced the signing of its largest traditional store development agreement in North America in over 20 years, accelerating growth of the Papa John's brand in the Philadelphia area. Under the agreement, HB Restaurant Group, which currently owns 43 restaurants in the Mid-Atlantic area and has been a Papa John's franchisee since April 2019, is to open 49 new stores in Philadelphia and southern New Jersey between 2021 and 2028.

08:03 EDT Target plans to increase representation of Black team members 20% over 3 years - As part of its longstanding commitment to creating a culture that is diverse, equitable and inclusive, Target released a detailed racial and gender breakdown of its team across all levels of the organization. Along with issuing the report, Target also announced plans to increase representation of Black team members across the company by 20% over the next three years by sharpening its focus on advancement, retention and hiring. "Inclusivity is a deeply rooted value at Target and we've had an ambitious diversity and inclusion strategy for many years for our guests and team. We know that having a diverse workforce and inclusive environment not only creates a stronger team, but also provides the perspectives we need to create the products, services, experiences and messages our guests expect," said Melissa Kremer, Chief Human Resources Officer. "The next step in this journey is being even more transparent with our progress by sharing a deeper look into the racial and gender diversity of our team, listening to our team's feedback along the way and using this information to drive a number of new commitments for our team."

07:53 EDT EbixCash handles travel needs for five of eight franchises in IPL event - EbixCash announced that it is handling the travel needs for five of the eight franchises involved in a 82-day Indian Premier League cricket sporting extravaganza in Dubai. Telecast in 8 languages, IPL is seen as one the most watched sporting events in the world with 2019 viewership of 462 million across TV and Digital. Under the leadership of the Mr. Naveen Kundu, Managing Director for EbixCash Tours & Travels, EbixCash has been able to secure this prestigious assignment that involves end to end needs for many franchises including chartered flights, ground transportation, foreign exchange, hotel rooms and event insurance coverage. As a part of this engagement of EbixCash independently by five of the IPL Franchises, EbixCash is handling - Approximately 19,000 plus hotel room night bookings for four franchises; Chartered flights for five franchises; Ground transportation for two franchises; Foreign exchange needs for entire entourage of four of the teams; Event insurance coverage for one team. Kings XI Punjab, Delhi Capitals, Rajasthan Royals, Kolkata Knight Riders and Chennai Super Kings are the five franchises who have engaged EbixCash Tours and Travels for varied travel needs of each of the franchises. The Indian Premier League is a professional Twenty20 cricket league in India contested every year by eight teams involving players from across the world, representing eight different cities in India.

07:39 EDT Turquoise Hill provides update on funding discussions with Rio Tinto - Turquoise Hill provides an update with respect to its engagement with the company's controlling shareholder, Rio Tinto, concerning the long-term funding of Oyu Tolgoi. On September 9, Turquoise Hill and Rio Tinto signed a non-binding Memorandum of Understanding to pursue a re-profiling of existing project debt in line with current cash flow projections. The MOU also reflects the parties' understanding with respect to the raising of supplemental senior debt, the process for identifying and considering other funding options, and the scope and timing for a Turquoise Hill equity offering to address any remaining funding gap with respect to Oyu Tolgoi. Turquoise Hill and Rio Tinto expect that a successful Re-profiling would reduce the currently-projected funding requirements of Oyu Tolgoi by up to US$1.4B. Turquoise Hill and Rio Tinto will further seek to extend political risk mitigation through the planned raising of SSD in the form of amortizing term loans to Oyu Tolgoi in the aggregate amount of up to $500M. The balance of the funding gap will need to be satisfied by way of a TRQ equity offering. In the MOU, the parties have recorded their shared objective of ensuring that any required equity offering is completed not less than 90 days prior to Turquoise Hill becoming unable to meet its obligations as they become due.

07:35 EDT Theratechnologies to develop tesamorelin for treatment of NASH - Theratechnologies announced that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis in the general population. It was recently published in JCI Insight, a peer-reviewed medical journal, that in HIV-associated NAFLD/NASH, tesamorelin has a positive effect on gene expression related to oxidative phosphorylation, decreased gene expression related to inflammation, tissue repair and cell division while improving gene expression associated with favorable hepatocellular carcinoma prognosis. Based on its unique mode of action, tesamorelin is designed to work upstream to reduce the accumulation of liver fat, which can lead to NASH. Theratechnologies intends to submit its Phase 3 study protocol to the United States Food and Drug Administration and the European regulatory agencies in the coming weeks. Subject to feedback from the regulatory agencies, the trial would involve approximately 650 patients with fibrosis scores of 2 and 3 and with a NAS score of at least 4 and also include a cohort of 50 people living with HIV. The enrollment of patients is planned for the first quarter of 2021. Patients will be treated for a period of 18 months. As per published regulatory guidelines, the primary endpoints will assess NAS score normalisation and absence of worsening of fibrosis stage, or fibrosis improvement greater than or equal to 1 stage and no worsening of NAS. Theratechnologies intends to use a new investigational formulation of tesamorelin, known as "F8", for the Phase 3 trial in NASH. In addition, a supplemental Biologics License Application is expected to be filed with the FDA in early 2022 in HIV-associated lipodystrophy using a convenient, multi-dose pen injector currently being developed for this new formulation. The F8 is patent protected in the U.S. until 2033 and until 2034 in major European countries. Furthermore, a notice of allowance was issued by the United States Patent and Trademark Office on a pending US patent application filed by the Massachusetts General Hospital in March 2020 relating to the treatment of hepatic disease using GHRH or analogues thereof. This patent application claims, amongst other things, a method for the treatment of NAFLD or NASH in a patient via the administration of tesamorelin. Theratechnologies has an exclusive license with the MGH to this patent application. Theratechnologies continues to explore the filing of additional patent applications in the NAFLD/NASH field.

07:32 EDT Shyft Group opening new manufacturing facility in Florida - Shyft Group plans to open a new 35,000-square-foot manufacturing facility in Jupiter, Florida. The facility will primarily be used for Strobes-R-Us specialty vehicle fleet upfit and retail sales, while providing the company's Utilimaster brand with additional regional manufacturing and assembly capacity. Production at the new Palm Beach County facility is expected to begin this fall. The expansion is expected to immediately create 40 new skilled trades positions.

07:13 EDT Myriad Genetics appoints Rashmi Kumar to board of directors - Myriad Genetics (MYGN) announced the election of Rashmi Kumar to its Board of Directors, effective immediately, expanding the Board to 12 members. Additionally, Ms. Kumar was appointed to the Audit and Finance Committee of Myriad's Board. Kumar is SVP and Global CIO of Hewlett Packard Enterprise Company (HPE).

07:11 EDT CoreLogic sends letter to shareholders regarding Senator and Cannae proposal - CoreLogic sent a letter to shareholders detailing CoreLogic's "outperformance," 2020 outlook and growth prospects for 2021 and 2022. The company said, "In light of Senator and Cannae's proposal to take control of our Board of Directors by removing and replacing nine directors with their hand-picked nominees, the letter also provides important facts about CoreLogic's highly qualified Board, which has deep industry experience and expertise with a proven track record of taking decisive action to transform the business and drive shareholder value." The letter said, "Since CoreLogic was established as an independent public company 10 years ago, we have successfully transformed our business into the market leader in residential property data and analytics. Today, we are a strategic partner to most of the key industry participants -- lenders, insurance carriers, investors, real estate professionals, and state and federal government entities. Since our spin-off, our long-term shareholders have realized significant returns on their investment from share price appreciation of more than 3x1 and over $1.5 billion in capital return. In recent years, we have invested heavily in the future -- building an unmatched "single source of truth" data repository for the US residential housing industry. Our new products and solutions are helping to automate and enhance housing finance, scaling our revenues in non-mortgage verticals and driving efficiency and profit margins to record levels. As a scaled market leader, we believe we are uniquely positioned to capitalize on these investments and important market trends to drive substantial further stock price appreciation for the benefit of our shareholders. Our investments and strong operational execution are delivering clear results. Over the past 12 months, we have achieved record financial results and our momentum is accelerating. Our shareholders are benefiting, and we believe we are poised for an increased trading multiple and higher market valuation. Our first half 2020 results have been exceptional and with further accelerating revenue growth, profit margins and free cash flow2, we expect 2020 will be a record year. Importantly, we expect to continue this strong momentum into 2021 and 2022. With Cannae's information advantage from inside knowledge of the industry, Senator/Cannae recognized our momentum and upside opportunity and launched an opportunistic, hostile bid to acquire CoreLogic at an inadequate price in the midst of the COVID-19 pandemic. Our robust outlook, growth trajectory, and conviction in our go-forward plan led our Board to reject Senator and Cannae's $65 per share acquisition proposal, based on the Board's unanimous determination that the bid significantly undervalues CoreLogic... Regardless of how you look at Senator and Cannae's acquisition proposal, it undervalues CoreLogic. When they made their hostile proposal, they valued CoreLogic at ~13x our previous FY 2020 guidance issued in February. If you apply that same 13x multiple to our current guidance issued on July 23rd, 2020, our implied stock price would be in the upper $70s, far above Senator and Cannae's $65 per share acquisition proposal. The Senator/Cannae proposal also fails to reflect any multiple expansion or any uplift from our new $1 billion capital return commitment -- even though our revenue trajectory and margin profile are now consistent with or above other information service providers that trade at higher multiples... In contrast, CoreLogic's directors have a deep knowledge of CoreLogic's business and industry as well as strong track records of successfully evaluating and executing public company M&A transactions. Eight of CoreLogic's directors have public M&A experience, including at Pinnacle Entertainment, Microsemi, LifeLock and aQuantive representing a combined transaction value of greater than $20 billion. This is a group that knows how to evaluate a potential transaction and sell when it makes sense. The Senator/Cannae nominees, on the other hand, are aligned with a low-value, high-risk proposal detrimental to shareholder interests. In summary, it is clear to us that the Senator/Cannae nominees have been hand-picked to force a sale to Senator and Cannae, not to maximize value for all shareholders. We believe the Senator/Cannae nominees seeking to gain control of your Board are an extension of Senator and Cannae's unsolicited acquisition proposal and must be viewed in that context. Senator and Cannae are focused on their own interest and agenda -- not the best interests of other CoreLogic shareholders."

07:10 EDT CareDx appoints Kashif Rathore as SVP, digital business - CareDx (CDNA) announced the appointment of new senior leaders to significantly strengthen key areas of the business - Digital Services, Laboratory Operations, Business Development, and Market Access. Kashif Rathore, Senior Vice President, Digital Business joins CareDx from Cerner (CERN), where he held various senior leadership roles. In addition to his most recent role as Vice President of Interoperability, Kashif served in the consulting and technology lines of Cerner's businesses. Ryan Phan, Vice President, Lab Operations joins CareDx from Kaiser Permanente, where he was the Managing Director and Head of Regional Molecular Genetics and Cytogenetics Laboratories. Sean Grant, Vice President, Strategy and Business Development joins CareDx from Citigroup Global Capital Markets (C), where he served as a Vice President in the Investment Banking Healthcare Division. Danielle Scelfo, Vice President, Market Access and Health Policy joins CareDx from Hologic (HOLX), where she was the Senior Director of Health Policy and Reimbursement.

07:08 EDT Ocular Therapeutix doses first patient in DEXTENZA Phase 3 clinical trial - Ocular Therapeutix announced that it has dosed the first patients in a Phase 3 clinical trial of DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain in children following cataract surgery. The Phase 3 clinical trial is a U.S.-based, randomized, multicenter clinical trial that intends to enroll approximately 60 subjects between the ages of 0-3 years.

07:07 EDT Anavex completes ANAVEX 2-73 U.S. Phase 2 Rett Syndrome trial - Anavex Life Sciences announced the completion of the ANAVEX 2-73 U.S. Phase 2 study in Rett syndrome. The Company expects to announce topline results from this study in the next quarter. ANAVEX 2-73 is an orally available, small-molecule activator of the sigma-1 receptor which, data suggest, is pivotal to restoring neural cell homeostasis and promoting neuroplasticity. The ANAVEX 2-73 U.S. Phase 2 study enrolled 31 patients with Rett syndrome and all patients completed the 7-week trial. The multi-center, double-blind clinical study at 8 sites across U.S. measured safety, tolerability, and efficacy of daily oral ANAVEX 2-73 doses or placebo. After completing the trial, eligible participants were able to join a voluntary open-label 12-week extension study of ANAVEX 2-73. Anavex previously reported interim data of the PART A intensive PK sub-cohort in the first 6 patients of the U.S. Phase 2 Rett syndrome study in which ANAVEX 2-73 that demonstrated significant improvements in the two global efficacy endpoints, the Rett Syndrome Behaviour Questionnaire Total score and the Clinical Global Impression - Improvement. ANAVEX 2-73 also significantly improved the RSBQ Hand Behaviours and RSBQ Breathing Abnormalities subscales. In addition, efficacy signals on both caregiver- and clinician-based measures of severity correlated with levels of glutamate, a key biomarker of disease pathogenesis. This study is one of three ongoing clinical studies in Anavex's Rett Syndrome Program: U.S. RTT, AVATAR and EXCELLENCE. ANAVEX 2-73 had previously received Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA for the treatment of Rett syndrome.

07:05 EDT Visa, PayPal expand partnership - Visa (V) said in a release, "Visa and PayPal (PYPL) shared details about an extension of their global partnership, which will expand real-time access to funds for consumers and small businesses that are sending or receiving money via PayPal, Venmo or Xoom. This collaboration expands PayPal's Instant Transfer service, which leverages Visa Direct for real-time payment capabilities, to global markets and enables fast domestic and cross-border digital payments. The global partnership will also enable PayPal to extend global white label Visa Direct payout services through PayPal and its Braintree, Hyperwallet and iZettle product solutions. This expansion follows the successful launch of the Instant Transfer service across North America and other markets in Asia Pacific and Europe."

07:03 EDT XPO Logistics extends technology partnership with MIT Industrial Liason Program - XPO Logistics has announced the renewal of its partnership with the Massachusetts Institute of Technology Industrial Liaison Program. In 2019, XPO became the first global logistics company to join the ILP, which pairs MIT's world-class research with leading corporations to advance innovation. The terms of the renewal are tailored to XPO's role as a technology leader in the supply chain industry. The ILP is structured to foster collaboration between XPO and MIT, providing these and other benefits: XPO continues to monitor emerging technologies that may be applied to solve transportation and logistics challenges. The company also has access to MIT's private knowledge base maintained by its faculty and researchers. The ILP's Startup Exchange connects XPO with innovations under development that may have significant supply chain benefits. The Startup Exchange has over 1,800 active MIT technology companies developing advances in nanotechnology, process efficiency, communications and other areas. MIT will continue to help XPO engage with MIT students for internships and job recruitment, identifying candidates who are a strong match with XPO's prioritization of customer service, productivity and intelligent technology.

07:02 EDT Immatics provides update on IMA204 ACTengine cell therapy program - Immatics provided an update on its fourth ACTengine cell therapy program, IMA204. IMA204 is designed to address a novel target, COL6A3 exon 6, which is highly expressed in the stroma of a large number of solid tumors. Immatics will discuss the IMA204 preclinical data at the Hanson Wade CAR-TCR Digital Week on September 14th. Preclinical data highlights: Exon 6 of the protein COL6A3 is predominantly expressed in the tumor stroma of multiple solid cancers including pancreatic cancer, breast cancer, gastric cancer, sarcoma, esophageal cancer, non-small cell lung cancer, squamous head & neck cancer, colorectal cancer, mesothelioma, ovarian cancer and others with prevalence estimates in these cancer types in the range of 40-80%. The tumor stroma target of IMA204 is an HLA-A*02-associated peptide derived from COL6A3 exon 6 with high copy numbers per cell identified by Immatics' proprietary mass spectrometry platform, XPRESIDENT. Over 90 different wild-type TCRs to this peptide were systematically evaluated using Immatics' platform, XCEPTOR. After TCR characterization, engineering and validation, two affinity-enhanced TCR candidates were selected. Both TCR candidates demonstrated promising preclinical properties including high avidity and specificity towards target-positive tumor cells based on XPRESIDENT-guided screening for off-target toxicity and cross-reactivity. In additional preclinical studies done in close collaboration with Jim Riley, Professor of Microbiology at the University of Pennsylvania, both product candidates showed tumor eradication in vitro and in vivo at physiological target expression levels. One of the two TCR candidates showed full CD8-independent target recognition and engaged both CD8+ and CD4+ T cells without the need for CD8 co-transduction. Based on recent studies Immatics believes that the additional activation of CD4+ T cells is potentially favorable for induction and maintenance of anti-tumor responses against solid cancers. After completion of ongoing final evaluation of the target and both TCR candidates, Immatics expects to submit an Investigational New Drug application to the US Food and Drug Administration for the IMA204 program in 2021.

06:58 EDT AstraZeneca to list U.S. ADR equity and all U.S. debt securities on Nasdaq - AstraZeneca announced that it will be transferring the listing of its American Depositary Receipts, or ADRs, and its U.S.-listed debt securities from the New York Stock Exchange to the Nasdaq Global Select Market and Nasdaq Bond Exchange respectively. The transfers will be effective after market close on Thursday, September 24. AstraZeneca ADRs and U.S.-listed debt securities are expected to commence trading on Nasdaq from Friday, September 25. The ADRs will continue to be listed under the ticker symbol "AZN". The company's primary listing in the UK on the London Stock Exchange and in Sweden on Nasdaq Stockholm are unaffected by the move. Marc Dunoyer, Executive Director and Chief Financial Officer, said: "The change of stock exchange in the US will reduce overall listing cost for our equity and debt securities. Further, as a global science-led, patient-focused biopharmaceutical company, dedicated to pushing the boundaries of science to deliver life-changing medicines, we are excited to be joining many of the world's largest and most innovative companies on Nasdaq."

06:51 EDT Nomad Foods announces preliminary results of tender offer - Nomad Foods announced the preliminary results of its "modified Dutch auction" tender offer for up to $500M of its ordinary shares which expired at 5:00 pm, New York City time, on September 9. Based on the preliminary count by the depositary for the tender offer, a total of 18,938,159 ordinary shares were validly tendered and not validly withdrawn at or below the price of $25.50 per share, including 7,921,070 shares that were tendered through notice of guaranteed delivery. In accordance with the terms and conditions of the tender offer and based on the preliminary count by the depositary, the company expects to repurchase a total of 18,938,159 ordinary shares through the tender offer at a price of $25.50 per share, for a total cost of $482,923,055, excluding fees and expenses. The total of 18,938,159 shares that the company expects to accept for repurchase represents approximately 9.6% of the company's total outstanding ordinary shares as of September 8.

06:47 EDT Stantec to partner with Battelle on 10-year, $260M ARSLS contract - Stantec will support Battelle on a 10-year, $260M Arctic Research Support and Logistics Services contract from the US Government's National Science Foundation. The team will provide infrastructure and logistics support to academic researchers conducting NSF-funded studies in Alaska, northern Canada, Greenland, and other Arctic areas. Specifically, Stantec will provide engineering, design, and planning services in support of new facilities as well as maintenance of existing facilities to enable research within some of the most remote locations, harsh weather conditions, and difficult terrain on Earth. The overall project scope will include the design of infrastructure and facilities in these remote locations. Plans include research facilities, laboratories, and operations centers that will facilitate efficient, effective, and safe research in the Arctic-a region critically important to the global research community. Stantec design features will enable sustainable and resilient facilities operation, including efficient startup and shutdown, reconfiguration and reuse over long lifespans, and remote monitoring/automation.

06:21 EDT TSMC reports August revenue NT$122.88B, up 15.8% y/y - TSMC announced its net revenues for August 2020: On a consolidated basis, revenues for August 2020 were approximately NT$122.88B, an increase of 16% from July 2020 and an increase of 15.8% from August 2019. Revenues for January through August 2020 totaled NT$850.14B, an increase of 30.7% compared to the same period in 2019.

06:11 EDT Macerich announces 44 of 47 retail properties reopened - Macerich said in a release, "Macerich announced that 44 of the Company's 47 major retail properties nationwide are now fully open for business. New easing of COVID-19-related restrictions in New York City and across most of California means Macerich's two major retail properties in New York City, along with six indoor California shopping centers, can once again welcome shoppers inside the malls. The two NYC properties, Kings Plaza in Brooklyn and Queens Center in Queens, reopened on Sept. 9 to lines of waiting shoppers. Recently reopened indoor properties in California include Fashion Fair in Fresno, Inland Center in San Bernardino, Pacific View in Ventura, The Mall at Victor Valley in Victorville, The Oaks in Thousand Oaks and Vintage Faire Mall in Modesto. Three additional indoor properties in California, all located in Los Angeles County - Lakewood Center in Lakewood, Los Cerritos Center in Cerritos and Stonewood Center in Downey - are expected to reopen as soon as county restrictions are relaxed, allowing 100% of Macerich properties nationwide to be reopened."

06:06 EDT Axonics reports final 2-year clinical results from Artisan-SNM pivotal study - Axonics has reported full 2-year clinical results from its Artisan-SNM pivotal study. Key clinical results at 2-years include: responder rate: 88% of all 129 implanted participants were therapy responders at 2-years, or greater than or equal to 50% reduction in urgency incontinence episodes compared to their baseline. Results are consistent with the 89% therapy responder rate reported at 1-year post implant. Completers analysis demonstrated 93% therapy responder rate at 2-years post implant. Urinary Urge Incontinence episodes declined from an average of 5.6 per day at baseline to 1.0 per day at 2-years. 80% of therapy responders had greater than or equal to75% reduction in their UUI episodes. 37% of therapy responders were dry, having experienced a 100% reduction in their UUI episodes. Participants experienced a clinically meaningful improvement in quality of life. 93% of participants reported being "satisfied" with their r-SNM therapy and they would undergo the procedure again. There were no serious device-related adverse events. The completion of 2-year follow-ups concludes the ARTISAN-SNM study. Axonics will continue to add to its body of clinical data with the Q4 launch of a multi-center registry study in the U.S. that will collect additional real-world clinical evidence on performance, safety and patient experience with the Axonics System across all approved clinical indications.

06:04 EDT Canopy Growth announces launch of Martha Stewart CBD - Canopy Growth announced the launch of Martha Stewart CBD, a new line of hemp-derived wellness supplements, with flavor profiles inspired by some of Martha's most popular recipes. The initial product offering will include a range of human wellness supplements, with a gift box and pet line launching later this year. The new portfolio of natural wellness gummies, softgels and oil drops are formulated by Martha Stewart, in collaboration with the cannabinoid scientists at Canopy Growth, to deliver a daily dose of pure, premium CBD isolate. Inspired by ingredients in Martha's own kitchen, the products are naturally flavored and are made in the USA with hemp-derived CBD isolate.

05:40 EDT PG&E says 97% of customers who can be restored now have power - PG&E said in a release, "Pacific Gas and Electric has restored power to approximately 97 percent of customers who can be restored and who were affected by the Public Safety Power Shutoff, or PSPS, event beginning late Monday night, September 7. Since daybreak, PG&E restored nearly 150,000 customers in 22 counties. Counties that are now fully restored include: Alpine, Amador, Calaveras, El Dorado, Kern, Lake, Lassen, Mariposa, Nevada, Placer, Siskiyou, Sonoma, Tehama and Tuolumne. For a group of customers mainly in the Northern Sierra, PG&E has not been able to restore electric service for three principal reasons: ongoing threats from wildfires, impacts from smoke impeding patrols, and requests from first responders to keep power lines off to assist in firefighting efforts. The company will resume patrols, repairs and re-energization on these lines in these areas as soon as first responders grant the company access and it is safe to do so. Approximately 5,000 customers who can receive service, but in areas where PG&E has not been able to perform patrols and inspections yet, are expected to remain out tonight in the following counties: Butte, Humboldt, Napa, Plumas, Sierra, Trinity and Yuba. Customers who are still without power tonight are expected to be restored by noon Thursday, if PG&E is able to patrol the remaining areas by helicopter. Once the severe weather subsided and the weather "all clear" was given to all 22 counties, PG&E began the patrol and restoration process. In weather "all clear" areas, PG&E crews began patrols on the ground early this morning to start inspecting more than 10,750 miles of transmission and distribution power lines for damage or hazards. Initially, PG&E paused some air inspections due to unsafe flying conditions caused by smoky and hazy skies but by noon, about half of PG&E's aircrafts were flying. PG&E crews began restoring customers in areas where they found no damage or hazards to electrical equipment. In areas where equipment was damaged by the severe wind event, the damages will be repaired before customers will be restored."

05:20 EDT Sanofi announces BIVV001 Phase 1/2a study results published in NEJM - The New England Journal of Medicine published positive final results from the Phase 1/2a trial evaluating the safety, tolerability and pharmacokinetics of BIVV001 in adult patients with severe hemophilia A. BIVV001 is an investigational factor VIII therapy designed to provide higher bleed protection in a once-weekly prophylactic treatment regimen. Sanofi and Sobi collaborate on the development and commercialization of BIVV001. "BIVV001 represents a potential new class of factor VIII replacement therapies. The sustained factor activity levels and three- to four-fold increase in half-life observed underscore its potential to provide near-normal bleed protection while reducing the dosing frequency of a prophylactic treatment to once a week," said Barbara Konkle, MD, lead investigator and Chief Scientific Officer, Bloodworks Northwest and Professor of Medicine/Hematology, University of Washington. "These results support the conclusion that BIVV001 may be a significant advancement for patients and we look forward to exploring this further in the ongoing Phase 3 study."